Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Net Income (2022 - 2025)

Stoke Therapeutics has reported Net Income over the past 4 years, most recently at -$57.8 million for Q4 2025.

  • Quarterly results put Net Income at -$57.8 million for Q4 2025, down 441.27% from a year ago — trailing twelve months through Dec 2025 was -$6.8 million (up 92.4% YoY), and the annual figure for FY2025 was -$6.8 million, up 92.3%.
  • Net Income for Q4 2025 was -$57.8 million at Stoke Therapeutics, down from -$38.3 million in the prior quarter.
  • Over the last five years, Net Income for STOK hit a ceiling of $112.9 million in Q1 2025 and a floor of -$57.8 million in Q4 2025.
  • Median Net Income over the past 4 years was -$25.7 million (2022), compared with a mean of -$18.9 million.
  • Peak annual rise in Net Income hit 527.99% in 2025, while the deepest fall reached 441.27% in 2025.
  • Stoke Therapeutics' Net Income stood at -$25.7 million in 2022, then decreased by 5.07% to -$27.0 million in 2023, then soared by 60.43% to -$10.7 million in 2024, then crashed by 441.27% to -$57.8 million in 2025.
  • The last three reported values for Net Income were -$57.8 million (Q4 2025), -$38.3 million (Q3 2025), and -$23.5 million (Q2 2025) per Business Quant data.